Spots Global Cancer Trial Database for Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Official Title: Phase I Study to Assess the Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573 in Solid Tumors
Study ID: NCT02405065
Conditions
Interventions
Study Description
Brief Summary: The main objective of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose of HM95573.
Detailed Description: Besides the main objective, there are 3 other objectives as follows: * To evaluate the anti-cancer effect of HM95573 in solid tumor patients * To investigate the pharmacokinetic profile of HM95573 after oral administration. * To investigate biomarkers related to the safety and efficacy of HM95573.
Keywords
Eligibility
Minimum Age: 20 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hanmi Clinical, Seoul, , Korea, Republic of
Contact Details
Name: Yohan Kim, MD
Affiliation: Hanmi Pharmaceutical co., ltd.
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
